Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Inocencio

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cancer Medicine|July 20, 2024
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trialKetty Peris, Timothy J Inocencio, Alexander J Stratigos, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 22, 2020
Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in TaiwanFang-Ju Lin, Kou-Gi Shyu, I-Chang Hsieh, et al.
Current Medical Research and Opinion|June 25, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myelomaNaresh Bumma, Hans C Lee, Joshua Richter, et al.
Leukemia & Lymphoma|July 10, 2026
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparisonJoshua Richter, Hans C Lee, Sundar Jagannath, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple MyelomaHans C Lee, Naresh Bumma, Joshua Richter, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cancer Medicine|July 20, 2024
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trialKetty Peris, Timothy J Inocencio, Alexander J Stratigos, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 22, 2020
Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in TaiwanFang-Ju Lin, Kou-Gi Shyu, I-Chang Hsieh, et al.
Current Medical Research and Opinion|June 25, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myelomaNaresh Bumma, Hans C Lee, Joshua Richter, et al.
Leukemia & Lymphoma|July 10, 2026
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparisonJoshua Richter, Hans C Lee, Sundar Jagannath, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple MyelomaHans C Lee, Naresh Bumma, Joshua Richter, et al.
Pageof 2